1033 related articles for article (PubMed ID: 34722051)
21. Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia.
Chuengsamarn S; Rattanamongkoulgul S; Suwanwalaikorn S; Wattanasirichaigoon S; Kaufman L
Bone; 2010 Apr; 46(4):1011-5. PubMed ID: 20045497
[TBL] [Abstract][Full Text] [Related]
22. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
Alberts AW
Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
[TBL] [Abstract][Full Text] [Related]
23. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
[TBL] [Abstract][Full Text] [Related]
24. Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig.
Conde K; Roy S; Freake HC; Newton RS; Fernandez ML
Lipids; 1999 Dec; 34(12):1327-32. PubMed ID: 10652993
[TBL] [Abstract][Full Text] [Related]
25. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Rackley CE
Clin Cardiol; 1996 Sep; 19(9):683-9. PubMed ID: 8874986
[TBL] [Abstract][Full Text] [Related]
26. [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
Perrot JL; Guy C; Bour Guichenez G; Amigues O; Servoz J; Cambazard F
Ann Dermatol Venereol; 1994; 121(11):817-9. PubMed ID: 7631993
[TBL] [Abstract][Full Text] [Related]
27. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
[TBL] [Abstract][Full Text] [Related]
28. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Serajuddin AT; Ranadive SA; Mahoney EM
J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
[TBL] [Abstract][Full Text] [Related]
29. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
30. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Desager JP; Horsmans Y
Clin Pharmacokinet; 1996 Nov; 31(5):348-71. PubMed ID: 9118584
[TBL] [Abstract][Full Text] [Related]
31. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.
Saheki A; Terasaki T; Tamai I; Tsuji A
Pharm Res; 1994 Feb; 11(2):305-11. PubMed ID: 8165193
[TBL] [Abstract][Full Text] [Related]
32. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Illingworth DR; Bacon S
Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
[TBL] [Abstract][Full Text] [Related]
33. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells.
Riessen R; Axel DI; Fenchel M; Herzog UU; Rossmann H; Karsch KR
Basic Res Cardiol; 1999 Oct; 94(5):322-32. PubMed ID: 10543307
[TBL] [Abstract][Full Text] [Related]
34. Effects of propionic acid and pravastatin on HMG-CoA reductase activity in relation to forestomach lesions in the rat.
Bueld JE; Bannenberg G; Netter KJ
Pharmacol Toxicol; 1996 Apr; 78(4):229-34. PubMed ID: 8861780
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Slater EE; MacDonald JS
Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
[TBL] [Abstract][Full Text] [Related]
36. Statins: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity.
Puttananjaiah MK; Dhale MA; Gaonkar V; Keni S
Appl Biochem Biotechnol; 2011 Jan; 163(2):215-22. PubMed ID: 20640529
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation.
White CM
J Clin Pharmacol; 1999 Feb; 39(2):111-8. PubMed ID: 11563401
[TBL] [Abstract][Full Text] [Related]
38. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
Morris MJ; Gilbert JD; Hsieh JY; Matuszewski BK; Ramjit HG; Bayne WF
Biol Mass Spectrom; 1993 Jan; 22(1):1-8. PubMed ID: 8431499
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
40. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
